Preliminary data indicate that RB1 wild-type tumors may have better outcomes when receiving NSCLC-type chemotherapy (platinum–gemcitabine or paclitaxel) than platinum–etoposide SCLC-like chemotherapy [118]. Here, RB1 is linked to non-small cell lung carcinoma.